

Fig. 2 MicroRNAs might use the same RNA-processing complex to direct silencing. Processing of the microRNA (*miRNA*) precursor hairpin (~70 nt) or long double-stranded RNA (dsRNA) would lead to single-stranded 21- to 23-nt RNA that is associated with the miRNA-protein complex (*miRNP*). This complex might direct either mRNA translation repression or mRNA target cleavage, depending on the degree of complementarity between the 21- to 23-nt RNA and the mRNA

species are produced by Dicer cleavage of longer (70 nt) endogenous precursors with imperfect hairpin RNA structures (Fig. 2). The miRNAs are believed to bind to sites that have partial sequence complementarity in the 3' untranslated region (UTR) of their target mRNAs, causing the repression of translation and the inhibition of protein synthesis (Pasquinelli and Ruvken 2002). More recently, Zeng et al. (2003) demonstrated that an endogenously encoded human miRNA was able to cleave an mRNA bearing fully complementary target sites, whereas an exogenously supplied siRNA could inhibit the expression of an mRNA bearing partially complementary sequences without inducing detectable RNA cleavage. These data suggest that miRNAs and siRNAs can use similar mechanisms to repress mRNA expression, and that the choice of mechanism might be largely, or entirely, determined by the degree of complementarity of the RNA target. In addition to Dicer, other PAZ/PIWI domain proteins (PPD), including eukaryotic translation-initiation factor 2C2 (eIF2C2), are likely to function in both pathways (Grishok et al. 2001; Hutvagner and Zamore 2002; Mourelatos et al. 2002).

Although the apparent lack of RNAi in mammalian cell culture was unexpected, yet RNAi has been found in mouse oocytes and early embryos (Svoboda et al. 2000; Wianny and Zernicka-Goetz 2000). Similarly, RNAi-related

transgenic-mediated co-suppression has been observed in cultured Rat-1 fibroblasts (Bahramian and Zarbl 1999). Notably, dsRNAs in the cytoplasm of mammalian cells have been reported to trigger profound physiological reactions that lead to the induction of interferon (IFN) synthesis (Lengyel 1987; Stark et al. 1998; Barber 2001). In the IFN response, dsRNAs that are longer than 30 bp bind and activate the protein kinase PKR and 2',5'-oligoadenylate synthetase (2',5'-AS) (Minks et al. 1979; Manche et al. 1992). Activated PKR suppresses translation by phosphorylating the translation-initiation factor eIF2 α , while activated 2',5'-AS causes mRNA degradation by stimulating RNase L. These responses are intrinsically sequence-non-specific with respect to the inducing dsRNAs.

2

Synthetic siRNAs

RNAi mediated by siRNAs is a powerful tool for dissecting gene function and drug-target validation. siRNAs can be synthesized in large quantities and thus can be used to analyze large numbers of sequences emerging from genome projects in a cost-effective manner. However, the phenomenon might reflect an incorrect sequence of RNAi, poor penetration of the mammalian cells by the nucleotides, or insufficient knowledge of the protein in question. siRNAs for gene-targeting experiments have only been introduced into cells via classic gene-transfer methods, such as liposome-mediated transfection, electroporation, and microinjection, all of which require the chemical or enzymatic synthesis of siRNAs (Donze and Picard 2002). Synthetic siRNA duplexes can be incubated with lipid formulations to generate liposomes containing siRNAs. In such formulations, cationic lipids bind to oligoribonucleotides through anion-cation and hydrophobic interactions. The efficiency of siRNA uptake is dependent upon the cell type. As high concentrations of cationic liposomes can be toxic, their application must be optimized for each type of target cell (Felgner et al. 1994). In particular, the transfection efficiency into suspension cells, such as T-cell lines and primary cells, using cationic liposomes is often less than 10%. Most of the cationic lipid reagents that are currently used for siRNAs are formulated as liposomes (lipofectamine) containing two lipid species: the polycationic lipid 2,3-diolexyloxy-*N*-[2(spermine-carboxamido)ethyl] *N,N*-dimethyl-1-propanaminium trifluoroacetate (DOSPA) and the neutral lipid dioleoylphosphatidylethanolamine (DOPE) (3:1 w/w). The efficient delivery of siRNAs by the lipofectamine reagent has been reported for siRNA-mediated RNAi in cultured mammalian cells (Caplen et al. 2001; Elbashir et al. 2001a; Garrus et al. 2001; Paul et al. 2002) and siRNA-mediated anti-acquired immunodeficiency syndrome (AIDS) therapeutics (Gitlin et al. 2002; Jacque et al. 2002; Novina et al. 2002; Park et al. 2002, 2003). The further development of liposomes might enhance their ability to deliver siRNAs to a broader range of target cells.

3

DNA Vector-Mediated siRNAs or Short Hairpin RNAs

siRNA-directed silencing by transfection is limited in mammals by its transient nature. To overcome some of the shortcomings of transfecting chemically synthesized siRNAs into cells, several groups have developed DNA vector-mediated mechanisms to express substrates that can be converted into siRNAs in vivo (Kennerdell and Carthew 2000; Tavernarakis et al. 2000; Svoboda et al. 2001; Brummelkamp et al. 2002a; Lee et al. 2002; McManus et al. 2002; Miyagishi and Taira 2002; Paddison et al. 2002a,b; Paul et al. 2002; Sui et al. 2002; Yu et al. 2002; Kawasaki and Taira 2003) (Fig. 3). Alternatively, small RNA molecules might also be expressed in cells following the cloning of siRNA templates into RNA polymerase III (pol III) transcription units, which are based on the sequences of the natural transcription units of the small-nuclear RNA (snRNA) U6 or the human RNase P RNA H1 (Medina and Joshi 1999; Paule and White 2000; Myslinski et al. 2001).

Two approaches have been used to express siRNA species through constructs that are driven by RNA pol III. In the first approach, the sense and antisense strands of the siRNA duplex are expressed from different, usually tandem, promoters (Fig. 3) (Lee et al. 2002; Miyagishi and Taira, 2002; Yu et al. 2002). In vivo, these strands come together to form a 19-nt duplex with 4-nt overhangs from the pol III-termination signal. The second approach uses Dicer to express and process short hairpin (sh)RNAs into siRNAs (Fig. 1). Dicer is required for the processing of pre-*let7* RNA—which is a structured, approximately 70-nt hairpin—into the mature, 22-nt active miRNA species (Reinhart et al. 2000; Grishok et al. 2001; Hutvagner et al. 2001; Knight and Bass 2001; Hutvagner and Zamore 2002). H1 RNA-pol III-based shRNA expression vector has been used to produce hairpin RNA with a 19-nt stem and a short loop (Brummelkamp et al. 2002a; Fig. 3). This system was used to inhibit the expression of E-cadherin (CDH1) and p53 with a comparable efficiency to siRNA transfection. Using RNA based on the *let7* precursor, *luciferase* mRNA has been targeted for degradation by including a 32-nt *luciferase*-complementary sequence in the stem of the hairpin (Paddison et al. 2002b). When transfected into *Drosophila* S2 cells, they found that although *let7*-based pre-*let7* RNA structures could target the *luciferase* mRNA, the most effective inhibitors had a simple hairpin structure with full complementarity in the stem. To express hairpin RNA in mammalian cells, they developed a U6 RNA-pol III-based expression system, which used a 29-nt sequence complementary to the luciferase gene and an 8-nt loop.

Although most expression systems use either the U6 or H1 promoter, an expression system that uses the transfer (t)RNA^{Val} promoter was described. shRNAs that have been generated using this expression system show a strong cytoplasmic localization and are efficiently processed by Dicer into siRNAs (Kawasaki and Taira 2003).




Fig. 3a–c Endogenous expression of short-interfering RNAs (siRNAs). **a** Long hairpin RNA expressed from an RNA polymerase (*pol II*) promoter yields a population of siRNAs with various sequence specificities. **b** An expression cassette for sense and antisense siRNAs using the tandem *pol III* small-nuclear RNA (snRNA) promoter. The preferred target site, which has been selected for optimal vector design, is indicated at the *bottom*. **c** A single *pol III* cassette for expressing hairpin RNAs that are subsequently processed to siRNAs. In this case, transcript synthesis is initiated with a +1 guanosine, and the 3' end of the sense strand is joined by short oligonucleotide loops with the antisense strand

Some investigators have employed viral vectors in order to facilitate the introduction of siRNA-expressing cassettes into cells. Human immunodeficiency virus type-1 (HIV-1)-based lentivirus vectors have attracted particular attention in this regard. These vectors exploit the ability of HIV-1 to infect non-dividing cells (Weinberg et al. 1991; Bukrinsky et al. 1992; Lewis et al. 2002). HIV-1-based lentivirus vectors retain this central characteristic and, as such, are particularly suitable for the transduction of non-dividing cells, such as neurons and hematopoietic progenitor cells (Naldini et al. 1996).

Lentivirus vectors expressing shRNAs have been shown to promote specific gene silencing in primary dendritic cells (Stewart et al. 2003), while CD8-specific shRNAs expressed from an HIV-1-based vector were capable of silencing CD8 expression both *in vitro* and *in vivo* (Rubinson et al. 2003). Collectively, these studies illustrate the broad utility of RNAi for the silencing of viral and cellular processes *in vitro* and *in vivo*.

4**Inhibition of HIV-1 Replication by RNAi**

The introduction of combination antiretroviral therapy has resulted in a remarkable improvement of the life expectancy of individuals infected with HIV and has significantly reduced their likelihood of developing AIDS. However, despite this progress, HIV infection remains incurable. Toxicity problems associated with current drug therapies and the emergence of drug resistance clearly indicate the need for alternative therapeutic approaches. Retroviral infection with HIV results in the stable integration of proviral DNA into the genome of target cells, and can therefore be viewed as an acquired genetic disease. Thus, the modulation of HIV replication by the expression of antiviral genes might be a therapeutic option for HIV infection. Baltimore (1988) was the first to suggest the concept of gene therapy as an intracellular immunization against HIV. Recently, numerous anti-HIV gene-therapy approaches have been developed and tested in clinical trials. These strategies can be divided into two main categories: first, the genetic modification of HIV target cells or their progeny in order to inhibit HIV replication and second, the genetic modification of cells in order to generate an immune response against HIV or HIV-infected cells. The latter category can be viewed as gene therapy-based immunotherapy and will not be discussed further in this review.

The inhibition of HIV replication involves the transfer of genetic material into HIV-1 target cells or their progenitors (CD4⁺ T cells or hematopoietic stem cells). A typical gene-therapy approach for HIV-1 infection is schematically depicted in Fig. 4. HIV-1 is well suited for target RNAi because dsRNAs act at multiple steps during the HIV-1 replication cycle (Fig. 4). The inhibitory proteins that are used against HIV act intracellularly and include antibody fragments, single-chain variable fragments, transdominant negative HIV, and cellular proteins. Most of these approaches target viral RNA or proteins. Additional cellular factors that are prerequisites for HIV infection or replication are also potential targets for anti-HIV gene therapy. A number of studies have reported that the transient transfection of siRNAs directed to several HIV-1 genes (*HIV-1 LTR*, *gag*, *vif*, *nef*, *tat* and *rev*) induced pre-integrated HIV-1 RNA degradation and consequently reduced HIV-1 antigen production by infected cells (Brummelkamp et al. 2002a; Capodici et al. 2002; Coburn and Cullen 2002; Jacque et al. 2002; Lee et al. 2002; Lewis et al. 2002; Novina et al. 2002; Paul et al. 2002; Surabhi and Gaynor 2002; Yamamoto et al. 2002; Yu et al. 2002; Song et al. 2003a). Lee and colleagues, and Banerjea and co-workers, demonstrated that a psiRNA approach can be used to inhibit the expression of HIV-1 *rev* and/or *tat* transcripts in transient transfections (Lee et al. 2002) or from lentiviral-transduced hematopoietic progenitor cells (Banerjea et al. 2003). In this approach, the vectors contain two tandem human U6 snRNA promoters followed by 21-mers encoding sense and antisense siRNAs. In co-transfection experiments, psiRNAs that were co-transfected with the HIV-1 pNL4-3 provi-




Fig. 4 RNA interference (RNAi) target sites in the human immunodeficiency virus type-1 (HIV-1) replication cycle. Short-interfering RNAs (siRNAs) that target HIV-1 RNA might induce the cleavage of pre-integrated RNA or interfere with post-integration HIV-1 RNA transcripts and block progeny virus production. siRNAs targeting CD4, CXCR4, or CCR5 RNA transcripts inhibit virus attachment to the CD4 receptor or chemokine receptor-mediated HIV-1 fusion and entry. As cleavage of the messenger RNA (mRNA) target requires a high degree of complementarity between the siRNA and its target sequence, heterogeneity in the virus population might prevent efficient silencing of some virus variants by specific siRNAs

ral DNA inhibited HIV-1 p24 antigen expression by up to 4 logs (Lee et al. 2002). This strong inhibition was achieved by simultaneously targeting two essential sites (*rev* and *tat*). Synthetic siRNAs targeted to HIV-1 *rev* and *tat* mRNAs were also shown to inhibit HIV-1 gene expression and replication in both human T cell lines and primary lymphocytes (Coburn and Cullen 2002).

Additional studies have demonstrated that siRNAs act at a later stage of the HIV-1 life cycle, causing post-integration degradation of HIV-1 RNA transcripts (Jacque et al. 2002; Lee et al. 2002; Novina et al. 2002).

The HIV-1 gag gene is expressed during the later steps of HIV-1 replication and encodes the gag-precursor protein, which is proteolytically cleaved into p24 and other polypeptides. p24 forms the HIV-1 core and functions by uncoating and packaging viral RNA. Novina et al. (2002) transfected cells with anti-gag siRNAs, exposed them to HIV-1, and observed a decrease in the in vitro production of p24. Co-transfections by Jacque et al. (2002) of a proviral

HIV-1 clone, 19-bp stem siRNAs directed against other HIV-1 genes (such as *vif* and LTR-*TAR*), and insertional mutagenesis of *nef* by a green fluorescent protein (GFP) gene, showed a significant suppression of virus production compared with non-transfected cells. Such siRNA- or shRNA-expression systems, if stable, might allow long-term target-gene suppression in cells (Naldini et al. 1996; Brummelkamp et al. 2002a; Lewis et al. 2002; Paddison et al. 2002b; Paul et al. 2002; Yu et al. 2002).

We demonstrated previously that dsRNAs specifically suppress the expression of HIV-1 genes (Park et al. 2002). In order to study dsRNA-mediated gene interference in HIV-1 infected cells, six long dsRNAs were designed to target the HIV-1 *gag* and *env* genes. HIV-1 replication was suppressed in a sequence-specific manner by these dsRNAs in infected cells. In particular, the E2 dsRNA, containing the major CD4 binding-domain sequence of gp 120 to target the HIV-1 *env* gene, dramatically inhibited the expression of the HIV-1 p24 antigen in peripheral blood mononuclear cells (PBMCs) for 2 weeks. More effective inhibition of HIV-1 replication was achieved using four siRNAs that were targeted to several regions of the HIV-1 *env* genes (Park et al. 2003). The mRNA targets for the siRNAs were selected from the middle of the *env* regions in the HIV-1 genome, as we previously showed that 531-bp (7.070–7.600) E2 dsRNAs complementary to the *env* mRNA-containing V3 loop and the major CD4 binding-domain sequence of gp 120 were more effective inhibitors than those targeted to the *gag* gene. Furthermore, the envelope protein (Env) of HIV-1 mediates functions that are critical to the viral life cycle, including viral attachment to target cells, and fusion of the viral and cellular membranes. We also showed the inhibition of HIV-1 replication in T cells using E2 shRNA directly from a lentivirus vector (Hayafune et al. 2005). On the other hand, we have shown that *vif* shRNA specifically suppresses the expression of HIV-1 (Barnor et al. in press). The HIV-1-encoded *vif* protein is essential for viral replication, virion production, and pathogenicity. HIV-1 *vif* interacts with the endogenous human APOBEC3G protein (an mRNA editor) in target cells to prevent its virions from encapsidation. Previous studies have established targets within the HIV-1 *vif* gene that are important for its biological function; however, it is important to determine effective therapeutic targets within *vif* because of its critical role in HIV-1 *vif*-dependent infectivity and pathogenicity. *vif* shRNAs increased the inhibition of HIV-1 replication in a long-term culture assay.

Rather than targeting the viral RNA, an alternative way of inhibiting virus replication by RNAi is to silence the expression of cellular genes that are critically involved in viral replication. For HIV-1, these targets include the mRNAs encoding the CD4 receptor and the CCR5 or CXCR4 co-receptors. These receptors are essential for attachment of the HIV-1 particle to the cell and for subsequent viral entry. RNAi against the viral RNA does not protect the cell against viral entry. By silencing these receptors, the HIV-1 particle will be unable to attach to, and enter, the cell, thus yielding a form of HIV-1 resistance.

Novina et al. (2002) showed that specific siRNAs that were directed against either CD4 or gag genes were able to prevent HIV-1 replication in MAGI and H9 cells. siRNA targeting rendered the receptor unavailable for virus attachment, thereby inhibiting HIV-1 entry and virus production. However, CD4 targeting might not be a feasible therapeutic approach because of its importance in immune function. By contrast, CCR5, which is the major HIV-1 co-receptor for viral entry into macrophages, might be a potentially useful cellular target, as a 32-bp homozygous deletion of the gene abolishes its function without deleterious immunological consequences and provides protection from HIV-1 infection (Martinez et al. 2002; Qin et al. 2003; Song et al. 2003a).

In this regard, RNAi is a powerful tool with which to determine the role of cellular co-factors in HIV-1 replication. Indeed, the first study to use RNAi in HIV-1 research silenced the expression of TSG-101, which is a component of the class E vacuolar protein-sorting pathway, by means of siRNAs (Garrus et al. 2001). This revealed a critical role for TSG-101 in the budding of HIV-1 virions. Moreover, when a lentivirus-based vector system was used to introduce shRNAs against CCR5 into peripheral blood T lymphocytes, the expression of CCR5 on the cell surface was reduced tenfold, resulting in a three- to sevenfold decrease in the number of infected cells (Qin et al. 2003). Lee et al. (2003) also showed inhibition of HIV-1 replication in macrophages using tat or CCR5 directly from a lentivirus vector. Similarly, siRNAs directed against CXCR4 co-receptors blocked HIV-1 entry, and protected cells from infection and delayed virus replication (Anderson et al. 2003). Another host factor that is important for HIV-1 replication is the transcription factor nuclear factor (NF)- κ B to motifs in the long terminal repeat (LTR) promoter of the integrated provirus is required for viral transcription (Surabhi and Gaynor 2002). However, targeting NF- κ B is not an appropriate therapeutic option, owing to the important role of NF- κ B in cells.

5 siRNA Agents Work as Ligands for Toll-Like Receptors

Surprisingly, recent studies have indicated that siRNAs can induce global up-regulation of the expression of IFN-stimulated genes (Bridge et al. 2003; Jackson et al. 2003; Sledz et al. 2003; Kariko et al. 2004; Persengiev et al. 2004; Fig. 5). This effect was detected with synthetic siRNAs that were transfected into cells, and with siRNAs that were produced within cells by the expression of shRNAs. Both of these papers documented significant non-specific changes in gene expression as a consequence of the delivery of siRNAs. Sledz et al. (2003) observed a 2-fold induction of 52 out of 850 putative IFN-stimulated genes using synthetic siRNAs. By contrast, Bridge et al. (2003) observed a 50-fold induction of the IFN-stimulated gene *OAS1* with one siRNA vector alone, and a 500-fold induction when two vectors were used simultaneously. These results suggest




Fig. 5 Toll-like receptor (TLR) signaling pathways. TLRs recognize molecular patterns associated with bacterial pathogens, double-stranded RNA and siRNA for TLR3; siRNA, UG-rich ssRNA, imidazoquinoline and its derivatives for TLR7/8. TLR signaling pathways are separated into two groups: (1) A MyD88-dependent pathway that leads to the production of pro-inflammatory cytokines with quick activation of NF- κ B and MAPK; and (2) TRIF, which may exist downstream of TLR3/4, and IKK ϵ and TBK1 to mediate the MyD88-independent pathways leading to production of IFN- β and IFN-inducible genes

that the ability to induce the IFN system depends on both the siRNA sequence and the method of delivery. Both groups pointed out that increasing the quantity of the siRNAs enhanced the effect. Furthermore, two recent studies have indicated that the mechanism of the IFN response might include recognition of the siRNAs by Toll-like receptor 3 (TLR3) (Heidel et al. 2004; Kariko 2004). One simple method for limiting the risk of inducing an IFN response is to use the lowest effective dose of shRNA vector, as advocated by Bridge et al. (2003).

Recently, Kim et al. (2004) showed that siRNAs synthesized using the T7 RNA polymerase system can trigger the apotent induction of IFN- α and - β in a variety of cells. The mediators of this response revealed that an initiating 5'-triphosphate was required for IFN induction. These findings have led to the development of an improved method for bacteriophage polymerase-mediated siRNA synthesis that incorporates two 3' adenosines in order to prevent base-pairing with the initiating Gs, thereby allowing RNase T1 and calf intestine alkaline phosphatase (CIP) to remove the initiating 5' nucleotides and triphosphates of the transcripts.

6 Virus Escape from RNAi

When profound inhibition of virus replication is obtained by means of RNAi technology, the possibility of viral escape must be considered. This potential

problem is particularly relevant for viruses that exhibit significant genetic variation due to an error-prone replication machinery.

This risk might be more severe for RNA viruses and retroviruses than for DNA viruses. The variability of HIV caused by its error-prone reverse transcriptase has been shown to generate mutations in the gene being targeted, thus allowing it to rapidly evade siRNAs (Boden et al. 2003). Similar results were observed for RNAi of a poliovirus infection (Gitlin et al. 2002). Synthetic siRNAs against poliovirus inhibited virus production 100-fold; however, the virus titer increased to high levels upon prolonged incubation. Sequence analysis of the progeny virus demonstrated a single escape mutation in the center of the siRNA target sequence. These findings indicate that the point mutation occurred in the middle of the signal target sequences. Two recent studies have demonstrated that transfection with siRNAs containing mismatches to the target sequence in the middle of the siRNA molecules reduces the efficiency of gene silencing (Brummelkamp et al. 2002b; Amarzguoui et al. 2003). These findings suggest that in order for RNAi to durably suppress HIV-1 replication, more potent shRNAs will need to be designed that can target highly conserved regions of the viral genome (for example, *gag* and *pol*) that are essential for the viral life cycle. Alternatively, RNAi constructs co-expressing multiple shRNAs could be developed that simultaneously target different regions of the viral genome, thereby reducing the probability of generating shRNA escape mutants.

7

Using RNAi to Treat Other Viruses

Although many previous studies on RNAi-mediated inhibition have focused on HIV-1, there is a growing body of data addressing the inhibition of other animal and human viruses. These include RNA viruses such as hepatitis C virus (HCV), poliovirus, Semliki Forest virus (SFV), influenza virus A, rhesus rotavirus (RRV), and Rous sarcoma virus (RSV), and DNA viruses such as human papillomavirus type 16 (HPV-16) and hepatitis B virus (HBV). In most of these studies, the RNAi machinery was directly targeted towards the viral RNA using synthetic siRNAs.

Hepatitis induced by HBV or HCV is a major health problem. At present, hundreds of millions of individuals are infected worldwide. Although there is an effective vaccine against HBV, it is only useful for the prevention of viral infection. There is no vaccine for HCV. Hepatitis caused by these two viruses has therefore been an important target for potential RNAi therapy.

The first demonstration of RNAi efficacy against a virus *in vivo* involved the hydrodynamic co-delivery of an HBV replicon and an expression unit encoding an anti-HBV shRNA in mice. HBV is a member of the family Hepadnaviridae and has a 3.2-kb circular dsDNA genome. During infection, four RNAs are transcribed, which encode the coat protein (CP), polymerase (P),

surface antigen (S), and transactivator of transcription (X). HBV production in Huh-7 cells was shown to be reduced by up to 20-fold through the transfection of a vector-expressing shRNA against the X mRNA (Shlomai and Shaul 2003).

Inhibition of HBV in the liver of mice was achieved through the co-transfection of HBV DNA and shRNA-expressing plasmids (McCaffrey et al. 2003), which resulted in a six fold decrease in the amount of secreted HBV surface antigen in the serum. This small-animal model of human infectious disease shows that it is possible to use RNAi as a potent antiviral therapy in mammals.

HCV is a major cause of chronic liver disease, which can lead to liver cirrhosis and hepatocellular carcinoma (Reed and Rice 2000). The HCV genome is a positive-strand RNA molecule with a single open reading frame encoding a polyprotein that is processed post-translationally to produce at least 10 proteins. HCV is a member of the family Flaviviridae and has a (+) single-stranded (ss)RNA genome.

Subgenomic and full-length HCV replicons that replicate and express HCV proteins in stably transfected human hepatoma-derived Huh-7 cells have been used to study the effects of various antiviral drugs (Lohmann, et al. 1999; Pietschmann, et al. 2001; Ikeda et al. 2002). Several groups have now tested the efficacy of the siRNA-mediated inhibition of replicon function using these systems (Kapadia et al. 2003; Randall et al. 2003; Wilson et al. 2003). These replicons support HCV RNA transcription and protein synthesis, but do not produce infectious viruses.

siRNAs targeted against sequences in the viral non-structural proteins NS3 and NS5B have been shown to cause profound (up to 100-fold) inhibition of HCV replicon function in cell cultures (Kapadia et al. 2003; Randall et al. 2003; Seo et al. 2003; Wilson et al. 2003). Furthermore, the internal ribosomal-entry site (IRES) in the well-conserved 5' UTR of the HCV RNA has also been a good target. Both siRNAs and shRNAs have been reported to inhibit HCV replicon function in cells (Seo et al. 2003; Wilson et al. 2003; Yokota et al. 2003; Hamazaki et al. 2005).

In another in vivo study, siRNAs were used to treat fulminant hepatitis induced by an agonistic Fas-specific antibody in mice (Song et al. 2003b). Fas-mediated apoptosis of hepatocytes can be triggered by HBV and HCV infection. Infusing siRNAs targeting Fas mRNAs into the tails of the mice blocked this self-destructive inflammatory response of the liver. These findings indicate that major hurdles remain before this therapy can be applied to humans.

As with HIV therapeutics, delivery of the siRNAs or shRNA vectors is the main challenge for the successful treatment of HCV.

Generally, human influenzal lesions are local infections that remain in the upper portion of the respiratory tract and do not proceed to pneumonia. Nevertheless, in high-risk patients, cases of influenzal pneumonia have been reported in which expansion of the virally infectious focus is observed in a pulmonary lesion. Furthermore, such cases are often accompanied by a secondary bacterial pneumonia. The influenza virus belongs to the family Orthomyxoviridae and

has a (-) ssRNA genome. Its genome is composed of eight separate segments. The proteins encoded by the eight segmented genes include HA and NA, as well as the M1 and M2 membrane proteins, which are located on the surface of the envelope. Furthermore, a nucleoprotein complex (RNP) is located at the center of the virus and is composed of the gene RNA, three RNA polymerase subunits (PB1, PB2, and PA) and a nucleoprotein (NP). A non-structural protein (NS) is synthesized from the eighth segmented gene. Amantadine and rimantadine are known antiviral agents for the influenza A virus; however, neither drug can cope with mutants and both have strong side effects (Atmar et al. 1990; Wang et al. 1993). Treatment by an inactivated vaccine has also been attempted; however, the vaccine cannot sustain antibody productivity for a long period and, thus, cannot completely prevent the spread of infection (Hirota et al. 1996).

Ge et al. (2003) showed that siRNAs targeting conserved regions (PA and NP) of the influenza genome inhibited virus production in cell culture and in embryonated chicken eggs. Furthermore, RNAi mediated by PA-, NP-, and PB1-specific siRNAs or shRNAs expressed from DNA vectors prevented and treated influenza A virus infection in mice (Ge et al. 2004). In addition, Tompkins et al. (2004) showed that the administration of influenza-specific siRNAs decreased lung virus titers and protected mice from lethal challenge by a variety of influenza A viruses, including the potential pandemic subtypes H5 and H7. This specific inhibition of influenza virus replication requires homology between the siRNAs and gene targets, and is not the result of IFN induction by dsRNAs. For therapeutic applications against the influenza A virus, the siRNAs can be administered via intranasal or pulmonary routes. RNAi is more potent than the antisense approach (Mizuta et al. 1999), and the evaluation of this technology as a treatment for the influenza virus through human clinical trials is expected to take place in the near future.

8 Concluding Remarks

While the results obtained to date should be considered preliminary in terms of their application to humans, they do provide strong justification for further investigations into the use of RNAi for the treatment of viruses in a clinical setting. The major problem with using RNAi as a tool to inhibit viral replication is the fact that it is still difficult to predict the effectiveness of specific siRNAs. It is clear from numerous studies that not all siRNAs are equally effective at generating an RNAi response. It has generally been assumed that siRNAs are under the control of the host interference-response mechanism. Recently, some expressed shRNAs have been shown to activate at least one of the arms of the human IFN-response mechanism. In addition, viral escape from RNA silencing is clearly a problem for developing effective RNAi-based antiviral therapy. Furthermore, some viral RNA sequences might be buried within

secondary structures or highly folded regions. Clearly, difficulties concerning the delivery, specificity, and effectiveness of siRNAs remain. However, once these fundamental questions have been addressed, it seems likely that RNAi therapy against viral infections will progress towards clinical trials.

Acknowledgements This work was supported in part by a Grant-in-Aid for High Technology Research from the Ministry of Education, Science, Sports, and Culture of Japan, a Grant from the Japan Society for the Promotion of Science as part of in the Research for the Future program (JSPS-RFTF97L00593) and a Research Grant from the Human Science Foundation (HIV-SA-14719). We thank Drs. Habu Y, Park W-S, Kusunoki A, Takahashi H, Barnor J, Hayafune M, and Hamazaki H for their contributions to the RNAi studies described here.

References

- Amarzguioui M, Holen T, Babaie E, Prydz H (2003) Tolerance for mutations and chemical modifications in a siRNA. *Nucleic Acids Res* 31:589–595
- Anderson J, Banerjee A, Planelles V, Akkina R (2003) Potent suppression of HIV type 1 infection by a short hairpin anti-CXCR4 siRNA. *AIDS Res Hum Retroviruses* 19:699–706
- Atmar RL, Greenberg SB, Quarles JM, Wilson SZ, Tyler B, Feldman S, Couch RB (1990) Safety and pharmacokinetics of rimantadine small-particle aerosol. *Antimicrob Agents Chemother* 34:2228–2233
- Bahramian MB, Zarbl H (1999) Transcriptional and posttranscriptional silencing of rodent alpha1(I) collagen by a homologous transcriptionally self-silenced transgene. *Mol Cell Biol* 19:274–283
- Baltimore D (1998) Gene therapy. Intracellular immunization [news]. *Nature* 335:395–396
- Banerjee A, Li M-J, Bauer G, Remling L, Lee N-S, Rossi J, Akkina R (2003) Inhibition of HIV-1 by lentiviral vector-transduced siRNAs in T lymphocytes differentiated in SCID-hu mice and CD34+ progenitor cell-derived macrophages. *Mol Ther* 8:62–71
- Barber GN (2001) Host defense, viruses and apoptosis. *Cell Death Differ* 2:113–126
- Barnor J, Miyano-Kurosaki N, Abuni Y, Yamaguchi K, Shiina H, Ishikawa K, Yamamoto N, Takaku H (2005) Lentiviral-mediated delivery of combined HIV-1 decoy TAR and vif-siRNAs as a single RNA molecule that cleaves to inhibit HIV-1 in transduced cells. *Nucleosides Nucleotides Nucleic Acids* 24 (in press)
- Bernstein E, Caudy AA, Hammond SM, Hannon GJ (2001) Role for a bidentate ribonuclease in the initiation step of RNA interference. *Nature* 409:363–366
- Billy E, Brondani V, Zhang H, Muller U, Filipowicz W (2001) Specific interference with gene expression induced by long, double-stranded RNA in mouse embryonal teratocarcinoma cell lines. *Proc Natl Acad Sci USA* 98:14428–14433
- Bitko V, Barik S (2001) Phenotypic silencing of cytoplasmic genes using sequence-specific double-stranded short interfering RNA and its application in the reverse genetics of wild type negative-strand RNA viruses. *BMC Microbiol* 1:34
- Boden D, Pusch O, Lee F, Tucker L, Ramratnam B (2003) Human immunodeficiency virus type 1 escape from RNA interference. *J Virol* 77:11531–11535
- Bridge AJ, Pebernated S, Ducraux A, Nicoulaz A-L, Iggo R (2003) Induction of an interferon response by RNAi vectors in mammalian cells. *Nat Genet* 34:263–264
- Brummelkamp TR, Bernards R, Agami R (2002a) A system for stable expression of short interfering RNAs in mammalian cells. *Science* 296:550–553
- Brummelkamp TR, Bernards R, Agami R (2002b) Stable suppression of tumorigenicity by virus-mediated RNA interference. *Cancer Cell* 2:243–247

- Bukrinsky MI, Sharova N, Dempsey MP, Stanwick TL, Bukrinskaya AG, Haggerty S, Stevenson M (1992) Active nuclear import of human immunodeficiency virus type 1 preintegration complexes. *Proc Natl Acad Sci USA* 89:6580–6584
- Caplen NJ, Fleenor J, Fire A, Morgan RA (2000) dsRNA-mediated gene silencing in cultured *Drosophila* cells: a tissue culture model for the analysis of RNA interference. *Gene* 252:95–105
- Caplen NJ, Parrish S, Imani F, Fire A, Morgan RA (2001) Specific inhibition of gene expression by small double-stranded RNAs in invertebrate and vertebrate systems. *Proc Natl Acad Sci USA* 98:9742–9747
- Capodici J, Kariko K, Weissman D (2002) Inhibition of HIV-1 infection by small interfering RNA-mediated RNA interference. *J Immunol* 169:5196–5201
- Coburn G, Cullen BR (2002) Potent and specific inhibition of human immunodeficiency virus type 1 replication by RNA interference. *J Virol* 76:9225–9231
- Donze O, Picard D (2002) RNA interference in mammalian cells using siRNAs synthesized with T7 RNA polymerase. *Nucleic Acids Res* 30:e46
- Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T (2001a) Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. *Nature* 411:494–498
- Elbashir SM, Lendeckel W, Tuschl T (2001b) RNA interference is mediated by 21- and 22-nucleotide RNAs. *Genes Dev* 15:188–200
- Elbashir SM, Martinez J, Patkaniowska A, Lendeckel W, Tuschl T (2001c) Functional anatomy of siRNAs for mediating efficient RNAi in *Drosophila melanogaster* embryo lysate. *EMBO J* 20:6877–6888
- Elbashir SM, Harborth J, Weber K, Tuschl T (2002) Analysis of gene function in somatic mammalian cells using small interfering RNAs. *Methods* 2:199–213
- Felgner JH, Kumar R, Sridhar CN, Wheeler CJ, Tsai YJ, Border R, Ramsey P, Martin M, Felgner PL (1994) Enhanced gene delivery and mechanism studies with a novel series of cationic lipid formulations. *J Biol Chem* 269:2550–2561
- Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC (1998) Potent and specific genetic interference by double-stranded RNA in *Caenorhabditis elegans*. *Nature* 391:806–811
- Garrus JE, von Schwedler UK, Pornillos OW, Morham SG, Zavitz KH, Wang HE, Wettstein DA, Stray KM, Cote M, Rich RL, Myszka DG, Sundquist WI (2001) Tsg101 and the vacuolar protein sorting pathway are essential for HIV-1 budding. *Cell* 107:55–65
- Ge Q, McManus MT, Nguyen T, Shen CH, Sharp PA, Eisen HN, Chen J (2003) RNA interference of influenza virus production by directly targeting mRNA for degradation and indirectly inhibiting all viral RNA transcription. *Proc Natl Acad Sci USA* 100:2718–2723
- Ge Q, Filip L, Bai A, Nguyen T, Eisen HN, Chen J (2004) Inhibition of influenza virus production in virus-infected mice by RNA interference. *Proc Natl Acad Sci USA* 101:8676–8681
- Gitlin L, Karelsky S, Andino R (2002) Short interfering RNA confers intracellular antiviral immunity in human cells. *Nature* 418:430–434
- Grishok A, Pasquinelli AE, Conte D, Li N, Parrish S, Ha I, Baillie DL, Fire A, Ruvkun G, Mello CC (2001) Genes and mechanisms related to RNA interference regulate expression of the small temporal RNAs that control *C. elegans* developmental timing. *Cell* 106:23–34
- Hamazaki H, Takahashi H, Miyano-kurosaki N, Shimotohno K, Takkau H (2005) Inhibition of HCV replication in HCV replicon cells by siRNAs. *Nucleosides Nucleotides Nucleic Acids* 24 (in press)
- Hannon GJ (2002) RNA interference. *Nature* 418:244–251

- Harborth J, Elbashir SM, Bechert K, Tuschl T, Weber K (2001) Identification of essential genes in cultured mammalian cells using small interfering RNAs. *J Cell Sci* 114:4557–4565
- Hayafune M, Miyano-Kurosaki N, Park W-S, Takaku H (2005) Silencing of HIV-1 gene expression by siRNAs in transduced cells. *Nucleosides Nucleotides Nucleic Acids* 24 (in press)
- Heidel JD, Hu S, Liu XF, Triche TJ, Davis ME (2004) Lack of interferon response in animals to naked siRNAs. *Nat Biotechnol* 22:1579–1582
- Hirota Y, Fedson DS, Kaji M (1996) Japan lagging in influenza jabs. *Nature* 380:18
- Hope IA (2001) Broadcast interference-functional genomics. *Trends Genet* 6:297–299
- Hutvagner G, Zamore PD (2002) A microRNA in a multiple-turnover RNAi enzyme complex. *Science* 297:2056–2060
- Hutvagner G, McLachlan J, Pasquinelli AE, Balint E, Tuschl T, Zamore PD (2001) A cellular function for the RNA-interference enzyme Dicer in the maturation of the let-7 small temporal RNA. *Science* 293:834–838
- Ikeda M, Yi M, Li K, Lemon SM (2002) Selectable subgenomic and genome-length dicistronic RNAs derived from an infectious molecular clone of the HCV-N strain of hepatitis C virus replicate efficiently in cultured Huh7 cells. *J Virol* 76:2997–3006
- Jackson AL, Bartz SR, Schelter J, Kobayashi SV, Burchard J, Mao M, Li B, Cavet G, Linsley PS (2003) Expression profiling reveals off-target gene regulation by RNAi. *Nat Biotechnol* 21:635–637
- Jacque JM, Triques K, Stevenson M (2002) Modulation of HIV-1 replication by RNA interference. *Nature* 418:435–438
- Kapadia SB, Brideau-Andersen A, Chisari FV (2003) Interference of hepatitis C virus RNA replication by short interfering RNAs. *Proc Natl Acad Sci USA* 100:2014–2018
- Kariko K, Bhuyan P, Capodici J, Ni H, Lubinski J, Friedman H, Weissman D (2004) Exogenous siRNA mediates sequence-independent gene suppression by signaling through toll-like receptor 3. *Cells Tissues Organs* 177:132–138
- Kawasaki H, Taira K (2003) Short hairpin type of dsRNAs that are controlled by tRNA(Val) promoter significantly induce RNAi-mediated gene silencing in the cytoplasm of human cells. *Nucleic Acids Res* 31:700–707
- Kennerdell JR, Carthew RW (2000) Heritable gene silencing in *Drosophila* using double-stranded RNA. *Nat Biotechnol* 18:896–898
- Ketting RF, Fischer SE, Bernstein E, Sijen T, Hannon GJ, Plasterk RH (2001) Dicer functions in RNA interference and in synthesis of small RNA involved in developmental timing in *C. elegans*. *Genes Dev* 15:2654–2659
- Kim DH, Longo M, Han Y, Lundberg P, Cantin E, Rossi JJ (2004) Interferon induction by siRNAs and ssRNAs synthesized by phage polymerase. *Nat Biotechnol* 22:321–325
- Kim SK (2001) Functional genomics: the worm scores a knockout. *Curr Biol* 11:R85–87
- Knight SW, Bass BL (2001) A role for the RNase III enzyme DCR-1 in RNA interference and germ line development in *Caenorhabditis elegans*. *Science* 293:2269–2271
- Lee MT, Coburn GA, McClure MO, Cullen BR (2003) Inhibition of human immunodeficiency virus type 1 replication in primary macrophages by using Tat- or CCR5-specific small interfering RNAs expressed from a lentivirus vector. *J Virol* 77:11964–11972
- Lee NS, Dohjima T, Bauer G, Li H, Li MJ, Ehsani A, Salvaterra P, Rossi J (2002) Expression of small interfering RNAs targeted against HIV-1 rev transcripts in human cells. *Nat Biotechnol* 20:500–505
- Lengyel P (1987) Double-stranded RNA and interferon action. *J Interferon Res* 5:511–519
- Lewis D, Hagstrom J, Loomis A, Wolff J, Herweijer H (2002) Efficient delivery of siRNA for inhibition of gene expression in postnatal mice. *Nat Genet* 32:107–108

- Lohmann V, Korner F, Koch J, Herian U, Theilmann L, Bartenschlager R (1999) Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. *Science* 285:110–113
- Manche L, Green SR, Schmedt C, Mathews MB (1992) Interactions between double-stranded RNA regulators and the protein kinase DAI. *Mol Cell Biol* 12:5238–5248
- Martinez MA, Gutierrez A, Armand-Ugon M, Blanco J, Parera M, Gomez J, Clotet B, Este JA (2002) Suppression of chemokine receptor expression by RNA interference allows for inhibition of HIV-1 replication. *AIDS* 16:2385–2390
- McCaffrey AP, Nakai H, Pandey K, Huang Z, Salazar FH, Xu H, Wieland SF, Marion PL, Kay MA (2003) Inhibition of hepatitis B virus in mice by RNA interference. *Nat Biotechnol* 21:639–644
- McManus MT, Sharp PA (2002) Gene silencing in mammals by small interfering RNAs. *Nat Rev Genet* 3:737–747
- McManus MT, Petersen CP, Haines BB, Chen J, Sharp PA (2002) Gene silencing using micro-RNA designed hairpins. *RNA* 8:842–850
- Medina MF, Joshi S (1999) RNA-polymerase III-driven expression cassettes in human gene therapy. *Curr Opin Mol Ther* 1:580–594
- Minks MA, West DK, Benveniste S, Baglioni C (1979) Structural requirements of double-stranded RNA for the activation of 2',5'-oligo(A) polymerase and protein kinase of interferon-treated HeLa cells. *J Biol Chem* 254:10180–10183
- Miyagishi M, Taira K (2002) U6 promoter-driven siRNAs with four uridine 3' overhangs efficiently suppress targeted gene expression in mammalian cells. *Nat Biotechnol* 20:497–500
- Mizuta T, Fujiwara M, Hatta T, Abe T, Kurosaki N, Shigeta S, Yokota T, Takaku H (1999) Antisense oligonucleotides directed against the viral RNA polymerase gene enhance survival of mice infected with influenza A. *Nat Biotechnol* 17:583–587
- Mourelatos Z, Dostie J, Paushkin S, Sharma A, Charroux B, Abel L, Rappsilber J, Mann M, Dreyfuss G (2002) miRNPs: a novel class of ribonucleoproteins containing numerous microRNAs. *Genes Dev* 16:720–728
- Myslinski E, Ame JC, Krol A, Carbon P (2001) An unusually compact external promoter for RNA polymerase III transcription of the human H1RNA gene. *Nucleic Acids Res* 29:2502–2509
- Nakano H, Amemiya S, Shiokawa K, Taira M (2000) RNA interference for the organizer-specific gene *Xlim-1* in *Xenopus* embryos. *Biochem Biophys Res Commun* 274:434–439
- Naldini L, Blomer U, Gallay P, Ory D, Mulligan R, Gage FH, Verma IM, Trono D (1996) In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. *Science* 272:263–267
- Novina CD, Murray MF, Dykxhoorn DM, Beresford PJ, Riess J, Lee SK, Collman RG, Lieberman J, Shankar P, Sharp PA (2002) siRNA-directed inhibition of HIV-1 infection. *Nat Med* 8:681–686
- Nykanen A, Haley B, Zamore PD (2001) ATP requirements and small interfering RNA structure in the RNA interference pathway. *Cell* 107:309–321
- Oates AC, Bruce AE, Ho RK (2000) Too much interference: injection of double-stranded RNA has nonspecific effects in the zebrafish embryo. *Dev Biol* 224:20–28
- Paddison PJ, Caudy AA, Hannon GJ (2002a) Stable suppression of gene expression by RNAi in mammalian cells. *Proc Natl Acad Sci USA* 99:1443–1448
- Paddison PJ, Caudy AA, Bernstein E, Hannon GJ, Conklin DS (2002b) Short hairpin RNAs (shRNAs) induce sequence-specific silencing in mammalian cells. *Genes Dev* 16:948–958
- Park WS, Miyano-Kurosaki N, Hayafune M, Nakajima E, Matsuzaki T, Shimada F, Takaku H (2002) Prevention of HIV-1 infection in human peripheral blood mononuclear cells by specific RNA interference. *Nucleic Acids Res* 30:4830–4835

- Park WS, Hayafune M, Miyano-Kurosaki N, Takaku H (2003) Specific HIV-1 env gene silencing by small interfering RNAs in human peripheral blood mononuclear cells. *Gene Ther* 10:2046–2050
- Parrish S, Fleenor J, Xu S, Mello C, Fire A (2000) Functional anatomy of a dsRNA trigger: differential requirement for the two trigger strands in RNA interference. *Mol Cell* 5:1077–1087
- Pasquinelli AE (2002) MicroRNAs: deviants no longer. *Trends Genet* 18:171–173
- Pasquinelli AE, Ruvkun G (2002) Control of developmental timing by microRNAs and their targets. *Annu Rev Cell Dev Biol* 18:495–513
- Paul CP, Good PD, Winer I, Engelke DR (2002) Effective expression of small interfering RNA in human cells. *Nat Biotechnol* 20:505–508
- Paule MR, White RJ (2000) Survey and summary: transcription by RNA polymerases I and III. *Nucleic Acids Res* 28:1283–1298
- Persengiev SP, Zhu X, Green MR (2004) Nonspecific concentration-dependent stimulation and repression of mammalian gene expression by small interfering RNAs (siRNA). *RNA* 10:12–18
- Pietschmann T, Lohmann V, Rutter G, Kurpanek K, Bartenschlager R (2001) Characterization of cell lines carrying self-replicating hepatitis C virus RNAs. *J Virol* 75:1252–1264
- Qin XF, An DS, Chen IS, Baltimore D (2003) Inhibiting HIV-1 infection in human T cells by lentiviral-mediated delivery of small interfering RNA against CCR5. *Proc Natl Acad Sci USA* 100:183–188
- Randall G, Grakoui A, Rice CM (2003) Clearance of replicating hepatitis C virus replicon RNAs in cell culture by small interfering RNAs. *Proc Natl Acad Sci USA* 100:235–240
- Reed KE, Rice CM (2000) Overview of hepatitis C virus genome structure, polyprotein processing and protein properties. *Curr Top Microbiol Immunol* 242:55–84
- Reinhart BJ, Slack FJ, Basson M, Pasquinelli AE, Bettinger JC, Rougvie AE, Horvitz HR, Ruvkun G (2000) The 21-nucleotide let-7 RNA regulates developmental timing in *Caenorhabditis elegans*. *Nature* 403:901–906
- Rubinson D, Dillon CP, Kwiatkowski AV, Sievers C, Yang L, Kopinja J, Rooney DL, Ihrig MM, McManus MT, Gertler FB, Scott ML, Van Parijs L (2003) A lentivirus-based system to functionally silence genes in primary mammalian cells, stem cells and transgenic mice by RNA interference. *Nat Genet* 33:401–406
- Schwarz DS, Hutvagner G, Haley B, Zamore PD (2002) Evidence that siRNAs function as guides, not primers, in the *Drosophila* and human RNAi pathways. *Mol Cell* 10:537–548
- Seo MY, Abrignani S, Houghton M, Han JH (2003) Small interfering RNA-mediated inhibition of hepatitis C virus replication in the human hepatoma cell line Huh-7. *J Virol* 77:810–812
- Sharp PA (2001) RNA interference. *Genes Dev* 15:485–490
- Shlomai A, Shaul Y (2003) Inhibition of hepatitis B virus expression and replication by RNA interference. *Hepatology* 37:764–770
- Sledz CA, Holko M, de Veer MJ, Silverman RH, Williams BR (2003) Activation of the interferon system by short-interfering RNAs. *Nat Cell Biol* 9:834–839
- Song E, Lee SK, Dykxhoorn DM, Novina C, Zhang D, Crawford K, Cerny J, Sharp PA, Lieberman J, Manjunath N, Shankar P (2003a) Sustained small interfering RNA-mediated human immunodeficiency virus type 1 inhibition in primary macrophages. *J Virol* 77:7174–7181
- Song E, Lee SK, Wang J, Ince N, Ouyang N, Min J, Chen J, Shankar P, Lieberman J (2003b) RNA interference targeting Fas protects mice from fulminant hepatitis. *Nat Med* 9:347–351
- Stark GR, Kerr IM, Williams BR, Silverman RH, Schreiber RD (1998) How cells respond to interferons. *Annu Rev Biochem* 67:227–264

- Stewart S, Dykxhoorn DM, Palliser D, Mizuno H, Yu EY, An DS, Sabatini DM, Chen IS, Hahn WC, Sharp PA, Weinberg RA, Novina CD (2003) Lentivirus-delivered stable gene silencing by RNAi in primary cells. *RNA* 9:493–501
- Sui G, Soohoo C, Affar el B, Gay F, Shi Y, Forrester WC, Shi Y (2002) A DNA vector-based RNAi technology to suppress gene expression in mammalian cells. *Proc Natl Acad Sci USA* 99:5515–5520
- Surabhi R, Gaynor R (2002) RNA interference directed against viral and cellular targets inhibits human immunodeficiency virus type 1 replication. *J Virol* 76:12963–12973
- Svoboda P, Stein P, Hayashi H, Schultz RM (2000) Selective reduction of dormant maternal mRNAs in mouse oocytes by RNA interference. *Development* 127:4147–4156
- Svoboda P, Stein P, Schultz RM (2001) RNAi in mouse oocytes and preimplantation embryos: effectiveness of hairpin dsRNA. *Biochem Biophys Res Commun* 287:1099–1104
- Tavernarakis N, Wang SL, Dorovkov M, Ryazanov A, Driscoll M (2000) Heritable and inducible genetic interference by double-stranded RNA encoded by transgenes. *Nat Genet* 24:180–183
- Tompkins SM, Lo CY, Tumpey TM, Epstein SL (2004) Protection against lethal influenza virus challenge by RNA interference in vivo. *Proc Natl Acad Sci USA* 101:8682–8686
- Tuschl T, Borkhardt A (2002) Small interfering RNAs—a revolutionary tool for analysis of gene function and gene therapy. *Mol Interv* 2:42–51
- Wang C, Takeuchi K, Pinto LH, Lamb RA (1993) On channel activity of influenza A virus M2 protein: characterization of the amantadine block. *J Virol* 67:5585–5594
- Weinberg JB, Matthews TJ, Cullen BR, Malim MH (1991) Productive human immunodeficiency virus type 1 (HIV-1) infection of non-proliferating human monocytes. *J Exp Med* 174:1477–1482
- Wianny F, Zernicka-Goetz M (2000) Specific interference with gene function by double-stranded RNA in early mouse development. *Nat Cell Biol* 2:70–75
- Wilson JA, Jayasena S, Khvorova A, Sabatino S, Rodrigue-Gervais IG, Arya S, Sarangi F, Harris-Brandts M, Beaulieu S, Richardson CD (2003) RNA interference blocks gene expression and RNA synthesis from hepatitis C replicons propagated in human liver cells. *Proc Natl Acad Sci USA* 100:2783–2788
- Yamamoto T, Omoto S, Mizuguchi M, Mizukami H, Okuyama H, Okada N, Saksena NK, Brisibe EA, Otake K, Fuji YR (2002) Double-stranded nef RNA interferes with human immunodeficiency virus type 1 replication. *Microbiol Immunol* 46:809–817
- Yokota T, Sakamoto N, Enomoto N, Tanabe Y, Miyagishi M, Maekawa S, Yi L, Kurosaki M, Taira K, Watanabe M, Mizusawa H (2003) Inhibition of intracellular hepatitis C virus replication by synthetic and vector-derived small interfering RNAs. *EMBO Rep* 4:1–7
- Yu JY, DeRuiter SL, Turner DL (2002) RNA interference by expression of short-interfering RNAs and hairpin RNAs in mammalian cells. *Proc Natl Acad Sci USA* 99:6047–6052
- Zamore PD (2002) Ancient pathways programmed by small RNAs. *Science* 296:1265–1269
- Zeng Y, Cullen BR (2002) RNA interference in human cells is restricted to the cytoplasm. *RNA* 8:855–860
- Zeng Y, Yi R, Cullen BR (2003) MicroRNAs and small interfering RNAs can inhibit mRNA expression by similar mechanisms. *Proc Natl Acad Sci USA* 100:9779–9784
- Zhao Z, Cao Y, Li M, Meng A (2001) Double-stranded RNA injection produces nonspecific defects in zebrafish. *Dev Biol* 229:215–223
- Zhou Y, Ching YP, Kok KH, Kung HF, Jin DY (2002) Post-transcriptional suppression of gene expression in *Xenopus* embryos by small interfering RNA. *Nucleic Acids Res* 30:1664–1669

THE MIDDLE TO 3' END OF THE HIV-1 VIF GENE SEQUENCE IS IMPORTANT FOR VIF BIOLOGICAL ACTIVITY AND COULD BE USED FOR ANTISENSE OLIGONUCLEOTIDE TARGETS

Jacob Samson Barnor □ *Department of Life and Environmental Science, Chiba Institute of Technology, Tsudanuma, Narashino, Chiba, Japan; and Noguchi Memorial Institute for Medical Research, Department of Virology, Legon, Accra-Ghana*

Naoko Miyano-Kurosaki and Hiroshi Takaku □ *Department of Life and Environmental Science and High Technology Research Center, Chiba Institute of Technology, Tsudanuma, Narashino, Chiba, Japan*

Kazuya Yamaguchi and Atsushi Sakamoto □ *Department of Life and Environmental Science, Chiba Institute of Technology, Tsudanuma, Narashino, Chiba, Japan*

Koichi Ishikawa and Naoki Yamamoto □ *National Institute of Infectious Diseases, AIDS Research Center, Toyama, Shinjyuku-ku, Tokyo, Japan*

Mubarak Osei-Kwasi and David Ofori-Adjei □ *Noguchi Memorial Institute for Medical Research, Department of Virology, Legon, Accra-Ghana*

□ *The human immunodeficiency virus type-1 (HIV-1)-encoded Vif protein is essential for viral replication, virion production, and pathogenicity. HIV-1 Vif interacts with the endogenous human APOBEC3G protein (an mRNA editor) in target cells to prevent its encapsidation into virions. Some studies have established targets within the HIV-1 vif gene that are important for its biologic function; however, it is important to determine effective therapeutic targets in vif because of its critical role in HIV-1 infectivity and pathogenicity. The present study demonstrates that virions generated in transfected HeLa-CD4⁺ cells, especially from HIV-1 vif frame-shift mutant (3'Δvif; 5561-5849), were affected in splicing and had low infectivity in MT-4 cells. In addition, HIV-1 vif antisense RNA fragments constructed within the same region, notably the region spanning*

In honor and blessed memory of the life and career of John A. Montgomery.

Received 19 January 2005; accepted 28 April 2005.

This work was supported in part by a Grant-in-Aid for High Technology Research, No. 09309011, from the Ministry of Education, Science, Sports, and Culture, Japan, by the Research Grant from the Human Science Foundation (HIV-SA-14719). This work was also partially supported by the Ministry of Education, Science, Sports and Culture, Grant-in-Aid for Scientific Research and partly by the Sasakawa Scientific Research Grant from the Japan Science Society.

Address correspondence to Hiroshi Takaku, Department of Life and Environmental Science and High Technology Research Center, Chiba Institute of Technology, Tsudanuma, Narashino, Chiba 275-0016, Japan. Fax: +81-47-471-8764; E-mail: hiroshi.takaku@it-chiba.ac.jp

nucleic acid positions 5561-5705 (M-3'-AS), which corresponds to amino acid residues 96-144, significantly inhibited HIV-1 replication in MT-4 and reduced the HIV-1 *vif* mRNA transcripts and reporter gene (EGFP) expression. The generated virions showed low secondary infection in H9 cells. These data therefore suggest that the middle to the 3' end of *vif* is important for its biological activity in the target cells.

Keywords HIV-1 *vif* gene; Antisense RNA; Oligonucleotides; Inhibition of HIV-1 replication; *Vif* biological activity

INTRODUCTION

Human Immunodeficiency Virus Type-1 (HIV-1) encodes six accessory proteins, Vpr, Vpu, Nef, Rev, Tat, and Vif, apart from its major structural Gag-Pol and Env proteins. The Vif protein is well conserved in all lentiviruses, except for the equine infectious anemia virus.^[1] The Vif-conserved lentiviruses include feline immunodeficiency virus, caprine arthritis encephalitis virus, bovine immunodeficiency virus, and simian immunodeficiency virus.^[2-4] The HIV-1 *vif* gene encodes a highly basic, 23000-M_r phosphoprotein that collapses intermediate filaments, localizes in the cytoplasm of its infected target cells, and acts during virus assembly by an unknown mechanism to enhance viral infectivity.^[5-9] HIV-1 Vif is viral- and cellular-specific,^[10,11] and is therefore critically essential for cells designated as non-permissive, such as H9, CEM, and U38, and is non-critical for cells classified as permissive, such as HeLa-CD4⁺, SupT1, COS, and Jurkat cells.^[12-16] HIV-1 Vif does not influence the expression or incorporation of the major encoded structural proteins.^[17] Hence, various studies have demonstrated that components such as viral proteins and nucleic acids were not changed in virions generated in non-permissive cells.^[13] On the other hand, deletions in the *vif* gene alter virion morphology in the same virus-producing cells.^[18-20] The HIV-1 Vif protein binds directly to the protease domain of the *pol* precursor, and thereby prevents improper cleavage of the *gag* precursor before viral assembly.^[21] Naturally occurring and C-terminally truncated variant HIV-1 Vif proteins lose this ability to bind Pol and affect Gag processing.^[8] Furthermore, Vif is an RNA-binding protein and is an integral component of the mRNP complex of viral RNA.^[22]

It has been hypothesized that the Vif protein functions by counteracting an unknown endogenous HIV inhibitor(s) in its target cells.^[10] It was recently demonstrated that CEM 15, now known as APOBEC3G, which is only expressed in non-permissive cells,^[23,24] is that endogenous inhibitor. When expressed in permissive cells, APOBEC3G makes the cells non-permissive. It is proposed to act in concert with other cellular factors such as sp140.^[25] The function of APOBEC3G is similar to that of APOBEC-1 (apoB mRNA editing catalytic subunit 1), a cytidine deaminase that converts cytidine into uridine in the mRNA of apolipoprotein B.^[26]